Zobrazeno 1 - 10
of 18
pro vyhledávání: '"William Grove"'
Autor:
William Grove-Fanning, Jennifer Rowland, Kerry Walker, Daniel Baskind, J. Baird Callicott, Robert Heath French
Publikováno v:
Environmental Values. 20:17-22
As a conservation policy advocate and practitioner, Leopold was a pragmatist (in the vernacular sense of the word). He was not, however, a member of the school of philosophy known as American Pragmatism, nor was his environmental philosophy informed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2de7598962a80c1d319ed82a000d2b4
https://doi.org/10.3197/096327111x12922350165950
https://doi.org/10.3197/096327111x12922350165950
Autor:
William Grove-Fanning
Publikováno v:
Southwest Philosophy Review. 26:119-130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03da3719417aa6c4bec9a30c35d1cfe3
https://doi.org/10.5840/swphilreview201026114
https://doi.org/10.5840/swphilreview201026114
Autor:
J. Baird Callicott, William Grove-Fanning, Jennifer Rowland, Robert Heath French, Kerry Walker, Daniel Baskind
Publikováno v:
Environmental Values. 18:453-486
Aldo Leopold was a pragmatist in the vernacular sense of the word. Bryan G. Norton claims that Leopold was also heavily influenced by American Pragmatism, a formal school of philosophy. As evidence, Norton offers Leopold's misquotation of a definitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44d4e1fa63aeb56ebf0c61c9e9476fed
https://doi.org/10.3197/096327109x12532653285812
https://doi.org/10.3197/096327109x12532653285812
Publikováno v:
Social Philosophy and Policy. 26:317-352
The Endangered Species Act of 1973 (ESA) is America's strongest environmental law. Its citizen-suit provision—permitting “any person” whomsoever to sue on behalf of a threatened or endangered species—awards implicit intrinsic value, de facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b065b77c97cca00d21ce661072b63167
https://doi.org/10.1017/s0265052509090268
https://doi.org/10.1017/s0265052509090268
Publikováno v:
Medicine. 84:350-362
We reviewed 106 patients referred to our institution for treatment of peripheral tuberculous adenitis to establish the epidemiologic, clinical, and pathologic manifestations of this disease. Tuberculous lymphadenitis occurred predominantly in young,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d4d15c509ea1171dc46a90338981df8
https://doi.org/10.1097/01.md.0000189090.52626.7a
https://doi.org/10.1097/01.md.0000189090.52626.7a
Autor:
Casey Cunningham, William Grove, Adrienne Williams, Douglas Orr, Stephen C. Olson, John Nemunaitis, Robert G. Mennel, Rob Eager
Publikováno v:
The Cancer Journal. 9:58-66
PURPOSE The purpose of this study was to determine the maximum tolerated dose, pharmacokinetic profile, and evidence of antitumor activity of CI-994 used in combination with gemcitabine. METHODS This was a dose escalation trial in which gemcitabine (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8a965c5464e6121740f8b770913701
https://doi.org/10.1097/00130404-200301000-00010
https://doi.org/10.1097/00130404-200301000-00010
Autor:
Ayers, William Grove
Recent demographic studies suggest a shift in consumer preference away from auto-centric suburban housing to more walkable suburban communities. In response to these changes, efforts have been made to model the walkability of a location and determine
Externí odkaz:
http://hdl.handle.net/10919/64350
Autor:
Creighton L. Edwards, Claire F. Verschraegen, John J. Kavanagh, Christina A. Meyers, Annette Hasenburg, Charles A. Conrad, Axel Grothey, Andrzej P. Kudelka, Datla G. Varma, William Grove, Arthur D. Forman, Ralph S. Freedman
Publikováno v:
Anti-Cancer Drugs. 9:405-409
CI-980 is a synthetic mitotic inhibitor that binds to tubulin at the colchicine site, inhibiting the polymerization of microtubules and arresting cellular division in metaphase. Myelosuppression and neurotoxicity were dose-limiting in phase I studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8fe3ee02d033ccb4748576480ec502
https://doi.org/10.1097/00001813-199806000-00006
https://doi.org/10.1097/00001813-199806000-00006
Autor:
Robert J. DeLap, William Grove, Bridget Flanagan, Steven A. Akman, Brian I. Carr, Doroshow Jh, Oluwole Odujinrin, Kim Margolin, Lucille Leong, David Goldberg
Publikováno v:
Investigational New Drugs. 8:369-376
3-Deazaguanine (Dezaguanine), a purine antimetabolite, was evaluated in a phase I trial in 42 patients with advanced solid tumors. Dezaguanine was given as a weekly intravenous infusion for three consecutive weeks of a four-week cycle. The dose range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c34f1d57aae92cf59413500000fc583
https://doi.org/10.1007/bf00198593
https://doi.org/10.1007/bf00198593
Autor:
Steven A. Akman, Brian I. Carr, Lucille Leong, William Grove, James H. Doroshow, Oluwole Odujinrin, Kim Margolin, David Goldberg
Publikováno v:
Medical and Pediatric Oncology. 18:49-52
Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma. Thirteen patients were evaluable for response and toxicity. Five patients had received prior treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d4397765c748ef39c9d9e5973b0a8fc
https://doi.org/10.1002/mpo.2950180110
https://doi.org/10.1002/mpo.2950180110